- Home
- OXBR vs BLRX Comparison
OXBR vs BLRX Comparison
Compare OXBR & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXBR
- BLRX
- Stock Information
- Founded
- OXBR 2013
- BLRX 2003
- Country
- OXBR Cayman Islands
- BLRX Israel
- Employees
- OXBR N/A
- BLRX N/A
- Industry
- OXBR Property-Casualty Insurers
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- OXBR Finance
- BLRX Health Care
- Exchange
- OXBR Nasdaq
- BLRX Nasdaq
- Market Cap
- OXBR 16.9M
- BLRX 17.0M
- IPO Year
- OXBR 2014
- BLRX 2011
- Fundamental
- Price
- OXBR $1.70
- BLRX $3.72
- Analyst Decision
- OXBR Strong Buy
- BLRX Strong Buy
- Analyst Count
- OXBR 1
- BLRX 2
- Target Price
- OXBR $5.00
- BLRX $19.00
- AVG Volume (30 Days)
- OXBR 79.9K
- BLRX 35.4K
- Earning Date
- OXBR 08-14-2025
- BLRX 08-14-2025
- Dividend Yield
- OXBR N/A
- BLRX N/A
- EPS Growth
- OXBR N/A
- BLRX N/A
- EPS
- OXBR N/A
- BLRX N/A
- Revenue
- OXBR $1,363,000.00
- BLRX $22,340,000.00
- Revenue This Year
- OXBR $497.99
- BLRX N/A
- Revenue Next Year
- OXBR $42.14
- BLRX N/A
- P/E Ratio
- OXBR N/A
- BLRX N/A
- Revenue Growth
- OXBR N/A
- BLRX 91.68
- 52 Week Low
- OXBR $1.27
- BLRX $2.30
- 52 Week High
- OXBR $5.81
- BLRX $35.02
- Technical
- Relative Strength Index (RSI)
- OXBR 41.77
- BLRX 36.88
- Support Level
- OXBR $1.63
- BLRX $3.35
- Resistance Level
- OXBR $1.85
- BLRX $4.17
- Average True Range (ATR)
- OXBR 0.20
- BLRX 0.29
- MACD
- OXBR -0.04
- BLRX -0.06
- Stochastic Oscillator
- OXBR 8.63
- BLRX 26.43
About OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.